← Back to Search

Virus Therapy

Live Attenuated Influenza Vaccine for Flu

Phase 4
Waitlist Available
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages 18-49 years old
not yet received influenza vaccine for 2019-2020,
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 2
Awards & highlights

Study Summary

This trial will help researchers develop a model for influenza infection, by administering the live attenuated influenza vaccine to healthy volunteers and measuring the virus and immune responses in their nasal passages.

Who is the study for?
Healthy adults aged 18-49 who haven't had the flu vaccine for the current season can join. They must be able to consent to participate. People with chronic health issues, recent respiratory infections, heart failure, Guillain-Barre syndrome, pregnancy, egg allergies or contact with immunocompromised individuals cannot join.Check my eligibility
What is being tested?
The study is testing a nasal spray flu vaccine called Flumist Quadrivalent to develop a model of influenza infection. Participants will receive this live vaccine and researchers will collect nasal samples to study virus presence and immune responses.See study design
What are the potential side effects?
As it's a live attenuated vaccine administered nasally, potential side effects may include nasal congestion or runny nose, sore throat, and possibly mild flu-like symptoms as the body responds to the vaccine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 49 years old.
Select...
I have not received the flu vaccine for 2019-2020.
Select...
I am able to understand and sign the consent form.
Select...
I am between 18 and 49 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 2
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
cystic fibrosis transmembrane conductance regulator function
influenza virus replication
markers of inflammation

Side effects data

From 2023 Phase 4 trial • 267 Patients • NCT05007041
8%
COVID-19 Infection
7%
Upper Respiratory Infection
1%
Cardiovascular Accident (CVA), Unspecified Mechanism
1%
Acute pulmonary embolism and acute deep vein thrombosis
1%
Left partial cranial nerve III palsy
1%
Acute Hyperkalemia
1%
Shortness of Breath
100%
80%
60%
40%
20%
0%
Study treatment Arm
Recombinant Zoster Vaccine (RZV) and High-Dose Quadrivalent Influenza Vaccine
Recombinant Zoster Vaccine (RZV) and Quadrivalent Adjuvanted Influenza Vaccine

Trial Design

1Treatment groups
Experimental Treatment
Group I: open labelExperimental Treatment1 Intervention
FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,594 Previous Clinical Trials
2,283,075 Total Patients Enrolled

Media Library

Flumist Quadrivalent Nasal Product (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04164212 — Phase 4
Influenza Research Study Groups: open label
Influenza Clinical Trial 2023: Flumist Quadrivalent Nasal Product Highlights & Side Effects. Trial Name: NCT04164212 — Phase 4
Flumist Quadrivalent Nasal Product (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04164212 — Phase 4
~3 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top